In contrast to cardiorenal syndrome ... should the enhancement of cardiovascular death initiated by kidney disease be termed 'renocardiac syndrome'? As the kidney is the primary regulator of ...

Cardiorenal syndrome (CRS) commonly occurs during treatment of acute decompensated heart failure (ADHF) and is associated with poor clinical outcome. The pathophysiology of CRS entails a complex ...

Aims We sought to assess the prevalence and clinical correlates of cardiorenal anaemia (CRA) syndrome in systolic heart failure and the relationship between renal dysfunction and anaemia on hard ...

The first kidney or cardiorenal outcome trial with an SGLT2 inhibitor, CREDENCE, was done in patients with type 2 diabetes, mostly because canagliflozin (Invokana, Janssen) was already on the ...

The following is a summary of “Association between triglyceride-glucose index and its composite obesity indexes and cardio-renal disease: analysis of the NHANES 2013-2018 cycle,” published in the ...

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed ...

The FDA’s Center for Biologics Evaluation and Research (CBER) granted Breakthrough Device Designation for the SCD in cardiorenal syndrome with LVAD in September 2023. “Oftentimes patients with ...

This is an important, but poorly understood, cause of morbidity and mortality in human and veterinary patients. The Comparative Cardiorenal Research Group is a unique collaboration between medical and ...

The FDA’s Center for Biologics Evaluation and Research (CBER) granted Breakthrough Device Designation for the SCD in cardiorenal syndrome with LVAD in September 2023. “Oftentimes patients with ...

In the last week, the United States market has stayed flat, yet it is up 24% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth and steady ...

The FDA’s Center for Biologics Evaluation and Research (CBER) granted Breakthrough Device Designation for the SCD in cardiorenal syndrome with LVAD in September 2023. “Oftentimes ...